NCT04358458 - First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2020

Primary Completion Date

November 21, 2022

Study Completion Date

July 28, 2023

Conditions

Diffuse Large B-cell LymphomaFollicular LymphomaMarginal Zone LymphomaSmall Lymphocytic LymphomaMantle Cell LymphomaChronic Lymphocytic LeukemiaHigh-grade B-cell LymphomaPrimary Mediastinal Large B-cell Lymphoma

Interventions

BIOLOGICAL

GEN3009

GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days

BIOLOGICAL

Epcoritamab

Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days

Trial Locations (17)

29425

Medical University of South Carolina (MUSC), Charleston

43210

Ohio State University, Columbus

44106

University Hospitals Cleveland Medical Center, Cleveland

75390

The University of Texas Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Center, Houston

80218

Colorado Blood Cancer Institute, Denver

98133

University of Washington - Seattle Cancer Care Alliance, Seattle

Unknown

UZ Leuven, Leuven

Rigshospitalet, Copenhagen

Odense Universitetshospital, Odense

Vejle Sygehus, Vejle

Amsterdam UMC, Locatie VUMC, Amsterdam

Hospital Clinic de Barcelona, Barcelona

Hospital Universitario Fundacion Jimenez Diaz, Madrid

08916

ICO Badalona - Hospital Universitari Germans Trias i Pujol, Badalona

08908

ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona